ABT-450 TOP |
 |
4-Week
Virologic Response and Safety of ABT-450
Given with Low-dose Ritonavir (ABT-450/r) First As 3-Day
Monotherapy Then in Combination with Pegylated Interferon
Alpha-2a and Ribavirin (SOC) in Genotype 1 (GT1) HCV-infected
Treatment-naïve Subjects |
|
Initial
Antiviral Activity of the HCV NS3 Protease Inhibitor ABT-450
When Given with Low-dose Ritonavir as 3-Day Monotherapy:
Preliminary Results of Study M11-602 in Genotype 1 (GT1)
HCV-infected Treatment-naïve Subjects |
Albumin Interfern
TOP |
|
Human
Genome Sciences Announces FDA Is Unlikely to Approve Albumin
Interferon Once Every 2 Weeks
6/22/2010 |
|
Human
Genome Sciences Submits FDA Licensing Application for
Albumin Interferon
(Zalbin) for Chronic Hepatitis C
12/08/09 |
|
Albumin Interferon (Albuferon) and
HCV Polymerase Inhibitor PSI-7851 Advance in Clinical
Trials
7/03/09 |
|
Review
Finds Albumin Interferon
for Chronic Hepatitis C Is Effective and Well-tolerated;
Phase 3 Results Show Non-inferiority to Pegylated Interferon
3/20/09 |
|
New
Hepatitis C Treatment Trials: HCV Polymerase Inhibitor
R7128, Nucleotide Prodrug IDX184, and
Albumin Interferon (Albuferon)
1/20/09 |
|
Albumin Interferon (Albuferon) Administered
Once Every 2-4 Weeks May Be As Effective as Once-weekly
Pegylated Interferon
9/23/08 |
|
Safety
and Activity of Once-Monthly
Albinterferon Alfa-2b (Albuferon) in Genotype
2/3 Chronic Hepatitis C Patients
5/23/08 |
|
Antiviral
Activity, Pharmacodynamics, and Quality of Life in Genotype
1 Hepatitis C Patients Treated with Albinterferon
(Albuferon)
5/23/08 |
|
Albuferon
Dose in Ongoing Trials is Lowered Due to Safety Concerns
1/25/08 |
Alisporivir
(Debio 025)
TOP |
|
Cyclophilin
Inhibitor Alisporivir
Active Against HCV in Phase 2b, HBV in Lab
4/08/2011 |
|
Debiopharm
Licenses Cyclophilin Inhibitor Alisporivir
(Debio 025) for Hepatitis C
2/12/2010 |
|
Debiopharm
Begins Randomization of Participants in Phase 2b Trial
of Cyclophilin Inhibitor Debio
025 for Chronic Hepatitis C
2/03/09 |
|
Cyclophilin
Inhibitor Debio-025
Demonstrates Potent Anti-HCV Activity in HIV-HCV Coinfected
Patients
3/14/08 |
ANA773
and ANA598
TOP |
|
Anadys
Starts Phase 2b Study of HCV Polymerase Inhibitor ANA598
2/01/2011 |
|
First
Cohort Dosing Completed in Clinical Trial of HCV Polymerase
Inhibitor ANA598
2/02/2010
|
|
First
Participants Treated in Phase 2 Trial of Anadys HCV Polymerase
Inhibitor ANA598
9/15/09 |
|
Experimental Interferon-inducer ANA773 Demonstrates
Antiviral Activity In Hepatitis C Treatment Trial
8/21/09 |
|
Data
on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916,
VCH-222, TMC435, ANA598,
MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09 |
BI
201335 and BI 207127
TOP |
|
BI201335
Shows Potent Activity against HCV |
|
BI
201335 for Hepatitis C Moves into Phase 3 Trials
4/29/2011 |
|
Direct-acting
Drug Combos Suppress HCV without Interferon, but Resistance
Remains a Concern
11/15/2010
|
|
Genotypic
and phenotypic analysis of the NS5B polymerase region
from viral isolates of HCV chronically infected patients
treated with BI 207127
for 5 days’ monotherapy
11/02/2010
|
|
Strong
antiviral activity and safety of IFN-sparing treatment
with the protease inhibitor BI
201335, the HCV polymerase inhibitor BI 207127,
and ribavirin, in patients with chronic hepatitis C: the
SOUND-C1 trial
11/02/2010
|
|
Virological
response and safety of 4 weeks’ treatment with the
protease inhibitor BI 201335
combined with 48 weeks of peginterferon
alfa 2a and ribavirin for treatment of HCV GT-1 patients
who failed peginterferon/ribavirin
11/02/2010
|
|
Experimental
HCV Protease Inhibitor BI 201335
Shows Robust Antiviral Activity in Genotype 1 Non-responders
4/23/2010 |
|
Experimental
HCV Protease Inhibitor BI 201335
Demonstrates Promising Results in Combination with Pegylated
Interferon and Ribavirin
11/06/09 |
|
SILEN-C1:
Early Antiviral Activity and Safety of BI
201335 Combined with Peginterferon alfa-2a
and Ribavirin in Treatment-naïve Patients with Chronic
Genotype 1 HCV infection
11/06/09 |
|
Virological
response and safety of BI 201335
protease inhibitor, peginterferon alfa 2a and ribavirin
treatment of HCV genotype-1 patients with compensated
liver cirrhosis and non-response to previous peginterferon/ribavirin
11/06/09 |
|
Investigational
HCV Protease Inhibitor BI 201335
Exhibits Promising Antiviral Activity
11/11/08 |
|
Safety and antiviral activity of BI 201335, a new HCV NS3 protease
inhibitor, in treatment-naïve patients with chronic hepatitis
C genotype 1 infection given as monotherapy and in combination
with peginterferon alfa-2a (P) and ribavirin (R)
11/05/08 |
|
Safety and antiviral activity of BI 201335, a new HCV NS3 protease
inhibitor, in combination therapy with peginterferon alfa-2a
(P) and ribavirin (R) for 28 days in P+R treatment-experienced
patients with chronic hepatitis C genotype 1 infection
11/05/08 |
BMS-650032,
BMS-790052 and BMS-824393
TOP
|
|
BMS-790052/BMS-650032
Combo Cures Hepatitis C without Interferon
4-12-2011 |
|
BMS-790052
+ Pegylated Interferon/Ribavirin Works Well for First
HCV Treatment
4-12-2011
|
|
Company
Collaboration to Test BMS-790052
+ PSI-7977 Combo for Hepatitis C
1-14-2010 |
|
Direct-acting
Drug Combos Suppress HCV without Interferon, but Resistance
Remains a Concern
11/15/2010
|
|
BMS-790052,
a First-in-Class Potent Hepatitis C Virus NS5A Inhibitor,
Demonstrates Multiple-Dose Proof-of-Concept in Subjects
With Chronic GT1 HCV Infection
11/02/2010 |
|
Coadministration
of BMS-790052 and
BMS-650032 Does Not Result in a Clinically Meaningful
Pharmacokinetic Interaction in Healthy Subjects
11/02/2010
|
|
Pipeline
Asset Update for BMS-790052
(NS5A inhibitor) and BMS-650032 (NS3 inhibitor)
11/02/2010
|
|
Combination
Therapy With BMS-790052
and BMS-650032 Alone or With Pegylated Interferon and
Ribavirin (pegIFN/RBV) Results in Undetectable HCV RNA
Through 12 Weeks of Therapy in HCV Genotype 1 Null Responder
11/02/2010
|
|
BMS-824393
Is a Potent Hepatitis C Virus NS5A Inhibitor With Substantial
Antiviral Activity When Given as Monotherapy in Subjects
With Chronic G1 HCV Infection |
|
HCV
NS5A Inhibitor BMS-790052
Suppresses Viral Replication in Combination with Pegylated
Interferon/ribavirin
4/28/2010 |
Boceprevir
(aka Victrelis)
TOP |
|
Boceprevir
(Victrelis) Approved for Hepatitis C
5-17-2011 |
|
Boceprevir
for HCV Wins Unanimous FDA Committee Recommendation
4-29-2011
|
|
FDA
Hearings Next Week on Boceprevir
and Telaprevir for HCV
4-23-2011 |
|
Boceprevir
Improves Response to Interferon-Based HCV Therapy
4-1-2011 |
|
FDA
Committee Sets Review Dates for HCV Drugs Boceprevir
and Telaprevir
3-18-2011
|
|
HCV
Protease Inhibitor Boceprevir
Improves Response for Treatment-Naive and Non-responders
3-15-2011 |
|
HCV
Protease Inhibitor Boceprevir
Accepted for Priority Review in U.S. and Europe
1-14-2010 |
|
Boceprevir
Improves Response to Interferon-based Therapy and Allows
Many Patients to Reduce Duration
11/02/2010
|
|
HCV
RESPOND-2 Final Results High Sustained Virologic Response
Among Genotype 1 Previous Non-Responders and Relapsers
to Peginterferon/Ribavirin when Re- Treated with Boceprevir
Plus PEGINTRON (Peginterferon alfa-2b)/Ribavirin
11/02/2010
|
|
Boceprevir
Combined with Peginterferon alfa-2b/Ribavirin
for Treatment-Naïve Patients with HCV Genotype 1
11/02/2010
|
|
Frequencies
of Resistance-Associated Amino Acid Variants Following
Combination Treatment with Boceprevir
Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavirin in Patients
With Chronic Hepatitis C (CHC), Genotype 1 (G1)
11/02/2010
|
|
Hemoglobin
Decline During Lead-in Phase as an Early Predictor of
Anemia After the Addition of Boceprevir:
A Retrospective Analysis of HCV SPRINT-1
11/02/2010
|
|
Response-Guided
Therapy with Boceprevir
+ Peginterferon alfa-2b/Ribavirin for Treatment-Naïve
Patients with Hepatitis C Virus Genotype 1 Was Similar
to a 48-Wk Fixed-Duration Regimen with Boceprevir + Peginterferon
alfa-2b/Ribavirin in SPRINT-2
11/02/2010
|
|
HCV
Protease Inhibitor Boceprevir
Increased Sustained Response to Interferon-based Therapy
in Phase 3 Studies
8/06/2010
|
|
Hope
Against Hepatitis C
7/23/2010
|
|
HCV
Protease Inhibitor Boceprevir
Demonstrates Durable Sustained Response with No Late Relapse
4/28/2010 |
|
SPRINT-1
Study Shows Benefits of Response-guided Therapy with Experimental
HCV Protease Inhibitor Boceprevir
11/06/09
|
|
Response-Guided
Therapy for Boceprevir Combination
Treatment? Results from HCV SPRINT-1
11/03/09 |
|
Schering-Plough
Completes Enrollment of Phase 3 Trials of Boceprevir
for Chronic Hepatitis C
6/26/09 |
|
Experimental
HCV Protease Inhibitor SCH 900518,
with or without Pegylated Interferon, Appears Safe and
Exhibits Good Antiviral Activity
5/01/09 |
|
Adding
Boceprevir to PegIntron/Ribavirin
Significantly Improves Sustained Virological Response
in Chronic Hepatitis C Patients
5/01/09 |
|
SAFETY
AND ANTIVIRAL ACTIVITY OF SCH
900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION
WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED
HCV-1 INFECTED PATIENTS
5/01/09 |
|
HCV
SPRINT-1 Final Results SVR 24 Boceprevir*
plus PegIFN alfa-2b/Ribavirin HCV 1 Treatment
Naïve Patients
5/01/09 |
|
Preclinical Characterization of SCH 900518, A Novel Mechanism-Based
Inhibitor of HCV NS3 Protease
4/24/09 |
|
A Regional Gastrointestinal Absorption Study
of the HCV NS3 Protease Inhibitor SCH 900518 in Healthy Volunteers
4/24/09 |
GI-5005
TOP |
|
Preliminary
Results Show Promising Response to Therapeutic Hepatitis
C Vaccine GI-5005
11/09/2010 |
|
HCV
Therapeutic Vaccine GI-5005
Improves Rate of Sustained Response to Interferon-based
Therapy for Hepatitis C
11/09/2010
|
|
Researchers
Report Promising Results from Studies of 3 Therapeutic
HCV Vaccines
5/19/2009
|
GS
9132 and GS 9190
(Tegobuvir) and GS 9450
TOP |
|
Tegobuvir
Works Well in Triple and Quad Regimens for HCV
4/23/2010
|
|
Gilead
Terminates Study of Caspase Inhibitor GS
9450 for Hepatitis C Due to Safety Concerns
4/20/2010 |
|
Data
on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916,
VCH-222, TMC435, ANA598, MK-7009, GS-9450,
Abbott/Enanta and Idenix Agents
5/12/09 |
|
Safety,
Tolerability, and Pharmacokinetics of GS-9450
in Healthy Male and Female Volunteers
4/24/09 |
IDX136,
IDX316, IDX320, IDX375 and IDX184
TOP |
|
FDA
Suspends Trials of Experimental HCV Regimen IDX184
plus IDX320 Due to Liver Toxicity Concerns
9/10/2010
|
|
Idenix
Begins Proof-of-Concept Study of HCV Protease Inhibitor
IDX320
6/18/2010 |
|
HCV
Polymerase Inhibitor IDX184,
Protease Inhibitor IDX320,
and Triple Combination Show Promising Antiviral Activity
5/04/2010
|
|
Vertex,
InterMune, and Idenix Present Hepatitis
C Drug Development Updates at Investor Conference
1/22/2010
|
|
IDX184,
A Liver-Targeted Nucleotide HCV Polymerase Inhibitor:
Results of a First-in-Man Safety and Pharmacokinetic Study
5/01/09 |
|
Antiviral Activity of the Liver-Targeted
Nucleotide HCV Polymerase Inhibitor IDX184
Correlates with Trough Serum Levels of the Nucleoside
Metabolite in HCV-infected Chimpanzees
5/01/09 |
|
Preclinical
Pharmacokinetic and Safety Profile of IDX375,
A Novel and Potent Non-Nucleoside HCV Polymerase Inhibitor
4/24/09 |
|
Preclinical
Profiles of IDX136 and IDX316, Two Novel
Macrocyclic HCV Protease Inhibitors
4/24/09 |
Locteron (Interferon)
TOP |
|
Controlled
Release Interferon (Locteron)
Every 2 Weeks Works as Well as Pegylated Interferon but
with Fewer Side Effects
5-18-10
|
|
OctoPlus
Initiates Phase IIa Study of Locteron
Controlled-release Interferon
2-22-08 |
IMO-2125
TOP |
|
Toll-like
Receptor Antagonist IMO-2125
Stimulates Production of Natural Interferons with Activity
against Hepatitis C Virus
12/13/09
|
|
Idera
Pharmaceuticals Begins Phase 1 Trial of Toll-like Receptor
Agonist IMO-2125 for
Chronic Hepatitis C
10/13/09 |
MK-5172,
MK-06080 and MK-7009
TOP |
|
Safety
and Antiviral Activity of MK-5172,
a Novel HCV NS3/4a Protease Inhibitor with Potent Activity
Against Known Resistance Mutants, in Genotype 1 and 3
HCV-Infected Patients
11/09/2010 |
|
Safety,
Tolerability, and Pharmacokinetics after Single and Multiple
Doses of MK-5172,
a Novel HCV NS3/4a Protease Inhibitor with Potent Activity
Against Known Resistance Mutants, in Healthy Subjects
11/09/2010
|
Sustained
Viral Response (SVR) Rates in Genotype 1 Treatment-naïve
Patients with Chronic Hepatitis C (CHC) Infection Treated
with Vaniprevir (MK-7009),
a NS3/4a Protease Inhibitor, in Combination with
Pegylated Interferon Alfa-2a and Ribavirin
for 28 Days
11/09/2010
|
|
Data
on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916,
VCH-222, TMC435, ANA598, MK-7009,
GS-9450, Abbott/Enanta and Idenix Agents
5/12/09 |
|
MK-7009
Significantly Improves Rapid Viral Response (RVR) in Combination
with Pegylated Interferon Alfa-2a and Ribavirin in Patients
with Chronic Hepatitis C (CHC) Genotype 1 Infection
4/24/09 |
|
|
|
Boosted
Narlaprevir plus
Pegylated Interferon and Ribavirin Leads to Rapid Viral
Suppression in Genotype 1 Hepatitis C Patients
11/10/09 |
Nitazoxanide
TOP
|
|
Nitazoxanide
Increases Response to Pegylated Interferon plus Ribavirin
in Treatment-naive and Non-responder Hepatitis C Patients
5-28-2010
|
|
Nitazoxanide
plus Pegylated Interferon and Ribavirin Produces Virological
Response in Some Prior Non-responders with Cirrhosis
11/10/09 |
|
Nitazoxanide
Enhances Anti-HCV Activity of Pegylated interferon/ribavirin
and STAT-C Agents
12/08/08
|
|
Nitazoxanide
Added to Standard Therapy Improves Response in Patients
with Genotype 4 HCV: STEALTH-C1 Study
5/08/08
|
Pegylated
Interferon Lambda
TOP |
|
Pegylated
Interferon Lambda Boosts Response with Few
Side Effects
4-5-2011 |
|
Pegylated
Interferon Lambda for Hepatitis C Produces
Good Response with Minimal Blood Toxicity
12/10/2010 |
|
The
Effect of Treatment Group, HCV Genotype, and IL28B Genotype
on Early HCV Viral Kinetics in a Phase 2a Study of PEG-Interferon
Lambda (pegIFNë) in Hepatitis C Patients
11/09/2010 |
|
Pegylated
Interferon Lambda (pegIFNë) Phase 2 Dose-Ranging,
Active-Controlled Study in Combination With Ribavirin
(RBV) for Treatment-Naive HCV Patients (Genotypes 1, 2,
3, or 4): Safety, Viral Response, and Impact of IL28B
Host Genotype Through Week 12
11/09/2010 |
|
Pharmacokinetics
of PEG-Interferon Lambda (pegIFNë)
Following Fixed Dosing in Treatment-Naive Hepatitis C
Subjects (Single-Dose Interim Data From a Dose-Ranging
Phase 2a Study)
11/09/2010 |
|
ZymoGenetics
Begins Phase 2b Trial of Pegylated
Interferon Lambda
6/08/10
|
|
Pegylated
Interferon Lambda Demonstrates Good Antiviral
Activity, May Cause Fewer Side Effects than Interferon
Alfa
11/03/09
|
PSI-879, PSI-938, PSI-7851,
PSI-7977 and PSI-938
TOP |
|
Company
Collaboration to Test BMS-790052 + PSI-7977
Combo for Hepatitis C
1-14-2010 |
|
Pharmasset
Starts Trial of HCV Polymerase Inhibitor PSI-7977
without Interferon
1-11-2011 |
|
HCV
Polymerase Inhibitor PSI-7977
Receives FDA Fast Track Designation
8/10/2010
|
|
Pharmasset
Starts New Phase 1b Clinical Trial of HCV Polymerase Inhibitor
PSI-938
7/30/2010
|
|
Combination
of 2 Nucleotide HCV Polymerase Inhibitors, PSI-7977
and PSI-938, Looks Good in Laboratory Study
5/11/2010
|
|
Pharmasset
Starts Trial of HCV Polymerase Inhibitor PSI-7977
for Genotype 1 Chronic Hepatitis C Patients
1/29/2010
|
|
Pharmasset
Selects Investigational HCV Polymerase Inhibitor PSI-879
for Preclinical Development
10/09/09
|
|
Pharmasset
Initiates First Clinical Trial of Second-generation HCV
Polymerase Inhibitor PSI-7851
4/10/09 |
|
Albumin
Interferon (Albuferon) and HCV Polymerase Inhibitor
PSI-7851 Advance in Clinical Trials
7/31/09 |
Danoprevir
(RG7227/ITMN-191)
TOP |
|
HCV
Protease Inhibitor Danoprevir
Promising in Early Trial
6/14/2011 |
|
Boosted
Danoprevir Improves
Response in Prior Null Responders
4/18/2011 |
|
Direct-acting
Drugs Danoprevir plus
RG7128 Suppress HCV without Interferon
10/22/2010
|
|
Roche
Acquires Rights to InterMune HCV Protease Inhibitor Danoprevir
10/08/2010
|
|
Experimental
HCV Polymerase Inhibitor RG7128
Is Effective with Standard Therapy in Genotype 2/3 Patients
4/23/2010 |
|
HCV
Protease Inhibitor Danoprevir
(RG7227/ITMN-191) Shows Antiviral Activity
at Lower Doses When Boosted with Ritonavir
4/20/2010 |
|
Vertex,
InterMune, and Idenix Present Hepatitis
C Drug Development Updates at Investor Conference
1/22/2010
|
|
Pharmasset
Announces Continuation of Phase 2b Trial of HCV Polymerase
Inhibitor RG7128
12/04/09 |
|
Oral
HCV Polymerase Inhibitor RG7128
plus Protease Inhibitor RG7227
(ITMN-191) Suppresses HCV Viral Load without
Interferon or Ribavirin
11/13/09 |
|
InterMune
and Roche Begins Trial of Ritonavir-boosted ITMN-191
(RG7227) for Genotype 1 Chronic Hepatitis C Patients
10/06/09 |
|
Roche and InterMune Begin
Phase 2b Trial of HCV Protease
Inhibitor RG7227/ITMN-191
9/04/09 |
|
Data
on Experimental Anti-HCV Drugs ITMN-191/R7227,
VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta
and Idenix Agents
5/12/09 |
|
New
Hepatitis C Treatment Trials: HCV Polymerase Inhibitor
R7128, Nucleotide
Prodrug IDX184, and Albumin Interferon (Albuferon)
1/20/09
|
|
HCV
Polymerase Inhibitor R7128 Demonstrates Good Antiviral
Activity in Genotype 2 or 3 Prior Non-responders and Relapsers
11/14/08 |
|
R7128 plus ITMN-191 Perform Well in
Laboratory Study; STAT-C Combination Clinical Trial Now
Underway
11/14/08
|
|
Natural
Prevalence of Resistance to HCV
Protease Inhibitors
9/25/08 |
|
Combination
Therapy with Investigational HCV Polymerase Inhibitor
R7128 Produces Rapid
Response in Patients with Genotype 2/3 HCV
9/12/08 |
Sorafenib
(Nexavar)
TOP |
|
Liver
Cancer Drug Sorafenib (Nexavar)
Inhibits Hepatitis C Virus Replication in Laboratory Study
1/08/10 |
SYC-635
TOP
|
|
Cyclophilin
Inhibitor SYC-635 May Reduce Fibrosis in Addition
to Inhibiting Hepatitis C Virus Replication
4/28/10
|
|
|
|
|
|
FDA
Committee Unanimously Recommends Telaprevir
5-03-2011 |
|
FDA
Hearings Next Week on Boceprevir and Telaprevir
for HCV
4-23-2011 |
|
Telaprevir
Improves HCV Cure Rates Regardless of IL28B Status
4-5-2011
|
|
|
|
Telaprevir
Combo Works for HCV Patients with Prior Unsuccessful Treatment
4-1-2011
|
|
|
|
HCV
Protease Inhibitor Telaprevir
Will Get Priority Review in U.S. and Canada
1-25-2011 |
|
|
|
|
|
|
|
Vertex
Begins Trial of Telaprevir
for Treatment-naive Chronic Hepatitis C Patients
10/29/2010 |
|
Telaprevir
Combination Therapy Boosts Sustained Response Rates for
Previously Treated Hepatitis C Patients
9/10/2010 |
|
Hope
Against Hepatitis C
7/23/2010 |
|
75%
of Treatment-naive Genotype 1 Hepatitis C Patients Achieve
Sustained Response with Telaprevir
Combination, Most with 24 Weeks of Therapy
6/08/2010 |
|
Many
Genotype 1 Hepatitis C Patients Can Be Cured with 24 Weeks
of Telaprevir plus
Pegylated Interferon/ribavirin
5/14/2010 |
|
Telaprevir
Monotherapy Is Potent against HCV Genotype 2 but Not 3,
Best Results when Combined with Interferon/ribavirin
5/14/2010 |
|
Prior
Non-responders Achieve Treatment Success with Telaprevir
plus Pegylated Interferon and Ribavirin
4/28/2010
|
|
Vertex
Will Study All-Oral Regimen of HCV Protease Inhibitor
Telaprevir plus Polymerase
Inhibitor VX-222
3/05/2010 |
|
Vertex,
InterMune, and Idenix Present Hepatitis
C Drug Development Updates at Investor Conference
1/22/2010 |
|
HCV
Protease Inhibitor Telaprevir
Demonstrates Good Efficacy in Both Treatment-experienced
and Treatment-naive Patients
11/10/09 |
|
Vertex
Aims to Receive $250 Million in Milestone Payments for
Anti-HCV Drug Telaprevir
after Approval in Europe
7/14/09 |
|
Adding
Telaprevir Improves
Sustained Response to Pegylated Interferon plus Ribavirin
in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/01/09 |
|
|
|
Tibotec
Begins Enrolling Phase III Study of HCV
Protease Inhibitor Telaprevir for Hepatitis
C Patients with Prior Treatment Failure
10/24/08 |
|
Telaprevir
plus Pegylated Interferon and Ribavirin Produces Rapid
Response and Is Well Tolerated in 28-day Study
7/22/08
|
|
|
|
Interim
Results Show TMC435
Works Well in Treatment-experienced Hepatitis C Patients
11/30/2010
|
|
Early
Analysis Finds Good Outcomes with Once-daily Dosing of
HCV Protease Inhibitor TMC435
11/15/2010 |
|
Efficacy
and Safety of TMC435
in Combination With Peginterferon a-2a and Ribavirin in
Treatment-naïve Genotype-1 HCV Patients: 24-Week
Interim Results from the PILLAR Study
11/15/2010
|
|
In
vitro studies investigating the mechanism of interaction
between TMC435 and
hepatic transporters
11/15/2010 |
|
Virologic
analysis of genotype-1-infected patients treated with
once-daily TMC435
during the Optimal Protease inhibitor Enhancement of Response
to TherApy (OPERA)-1 study
11/15/2010 |
|
A
Phase IIa, open-label study to assess the antiviral activity
of TMC435 monotherapy
in patients infected with HCV genotypes 2–6
11/15/2010 |
|
Pharmacokinetic-pharmacodynamic
analyses of TMC435
in patients infected with hepatitis C virus genotypes
2–6
11/15/2010 |
|
Protease
Inhibitor TMC435 Shows
Potent and Sustained Efficacy for Genotype 1 Chronic Hepatitis
C
8/24/2010 |
|
Investigational
HCV Inhibitor TMC435
Demonstrates Promising Safety and Efficacy in Phase 1
Study
4/02/2010 |
|
Data
on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916,
VCH-222, TMC435, ANA598,
MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09 |
|
OPERA-1 trial (Study TMC435-C201): interim
analysis of safety and antiviral activity of TMC435 in
treatment-naïve genotype-1 HCV patients
5/01/09 |
|
Antiviral activity and safety of TMC435 combined with peginterferon -2a and ribavirin
in patients with genotype-1 hepatitis C infection who
failed previous IFN-based therapy
5/01/09 |
|
Experimental
HCV Protease Inhibitor TMC435350
Demonstrates Favorable Safety and Efficacy
in Phase 2a Trial
11/11/08 |
|
Experimental
HCV Protease Inhibitor TMC435350
Demonstrates Promising Activity and Tolerability in Early
Clinical Trial
5/13/08 |
VCH-759, VCH-916, VCH-222
TOP |
|
Data
on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916,
VCH-222, TMC435,
ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09 |
|
Vertex
Acquires VCH-222 and
VCH-759, Two Experimental
Oral HCV Polymerase Inhibitors
3/15/09
|
|
Naturally
Occurring Resistance to HCV Protease
and Polymerase Inhibitors in Treatment-naive
Hepatitis C Patients
1/09/09 |
|
Natural
Prevalence of Resistance to HCV
Protease Inhibitors
9/25/08 |
Viramidine
(Taribavirin)
TOP
|
|
Weight-based
Taribavirin Works
as Well as Ribavirin for Chronic Hepatitis C, but Causes
Less Anemia
10/01/2010
|
|
Vertex,
InterMune, and Idenix Present Hepatitis
C Drug Development Updates at Investor Conference
1/22/2010 |
|
Viramidine
Fails to Show Non-inferiority to Ribavirin at Tested Doses,
but Causes Less Anemia
1/19/2010 |
|
Prodrug Taribavirin Produces Equivalent
Response, but Less Anemia than Ribavirin at 48 Weeks
12/02/08 |
|
Taribavirin Efficacy Similar to Ribavirin
in Combination Therapy for Hepatitis C, but with Less
Anemia
5/09/08
|
|
Valeant
Reports Promising 12-week Phase IIb Data on Taribavirin
4/01/08 |
